Physician profile
George Philips
NPI 1013120344
$725.15
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $15.58 · 2021: $148 · 2022: $256.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.74 | 2019-2022 | |
| Boston Scientific Corporation | $110.00 | 2021 | |
| Pfizer INC. | $74.73 | 2019-2021 | |
| Olympus America INC. | $44.70 | 2019 | |
| Celgene Corporation | $24.97 | 2022 | |
| Merck Sharp & Dohme LLC | $23.44 | 2022 | |
| Philips North America LLC | $21.26 | 2019 | |
| Ucb, INC. | $21.16 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.83 | 2022 | |
| Abbott Laboratories | $20.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2022 | |
| Braintree Laboratories, INC. | $13.11 | 2019 | |
| Ambu INC. | $5.37 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Philips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.